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ABSTRACT: The neuronal protein R-synuclein (R-syn) plays a central role in Parkinson’s disease (PD).
The pathological features of PD are the loss of dopaminergic neurons in the substantia nigra pars compacta
and the presence of Lewy bodies. The C-terminal domain ofR-syn is characterized by the presence of 15 acidic
amino acids and all five proline residues of the protein (P108, P117, P120, P128, and P138). The aggregation of
this natively unfolded protein is accelerated in vitro by FK506 binding proteins (FKBPs) showing
peptidyl-prolyl cis-trans isomerase activity. These proteins catalyze the cis-trans conformational change
of the X-Pro peptide bond, often a rate-limiting step in protein folding. The acceleration of the folding of
R-syn by FKBPs may accelerate disease-associated aggregation. To further elucidate the role of the proline
residues in the conformation and aggregation of R-syn, we constructed several mutants of R-syn in which one
or more proline residues are mutated to alanine via site-directed mutagenesis. For this purpose, we produced
and purified His-WT R-syn, a recombinant R-syn with a polyhistidine tag (six His residues) and a linker, and
a number of Pro-to-Ala mutants. The aggregation kinetics of these mutants and His-WT R-syn were studied
by turbidity, thioflavin T fluorescence, and CDmeasurements. We can conclude that mutation of the proline
residues to alanine accelerates the aggregation kinetics ofR-synwhile all prolinemutants formed fibrils similar
to His-WT R-syn, as visualized via transmission electron microscopy. We also demonstrate that the
accelerating effect of hFKBP12 is abolished via removal of the proline residues from the C-terminus. Finally,
we show that themutant ofHisR-synwith all five proline residuesmutated to alanine ismore structured (more
R-helix) thanHis-WT R-syn, indicating the role of the Pro residues as potential helix breakers in the inhibitory
conformation of the C-terminus.
Aggregation of unstructured proteins is a key element in
several neurodegenerative diseases such as Parkinson’s disease
(PD)1 and Alzheimer’s disease (AD) (1). The pathological
features of PD are a loss of dopaminergic neurons in the
substantia nigra pars compacta and the presence of Lewy bodies
(LB). LB are intracellular inclusions mainly composed of amy-
loid fibrils of R-synuclein (R-syn) (2). It has been implied that
small oligomers rather than fibrils are the toxic species of
R-syn (3, 4). R-syn was also genetically linked to PD by the
discovery of three point mutations that cause a familial form of
PD (5-7). Moreover, it was shown more recently that locus
duplication or triplication of the WT R-syn gene causes familial
forms of PD (8, 9).
Finally, the central role of R-syn in PD was corroborated
experimentally in different animal models in which overexpres-
sion leads to formation of neuronal inclusions and motoric
symptoms reminiscent of PD (10-12).
R-syn contains three domains. The N-terminal part (amino
acids 1-60) forms R-helices when bound to vesicles (13). The
central NAC domain (amino acids 61-95) is necessary and
sufficient for aggregation (14, 15), and the C-terminal domain
(amino acids 96-140) contains 15 acidic side chains (10 Glu and
5 Asp residues) but also the only five proline residues of the
protein (P108, P117, P120, P128, and P138). Deletion of the
C-terminus enhances the aggregation rate of R-syn (16, 17).
Consequently, the C-terminal part is considered as a regulatory
part of the protein. Remarkably though, this negatively charged
domain is not incorporated into the fibrils (18, 19).
R-syn is a natively unfolded protein in solution that can adopt
an ensemble of conformations without rigid structure but
stabilized by long-range tertiary interactions. On the basis of
NMR studies, it was suggested that these long-range interactions
between the NAC and C-terminal domain inhibit fibril forma-
tion (20). It was also shown thatMet oxidation strengthens these
long-range interaction and leads to the formation of stable
nontoxic oligomers (21).
The aggregation of R-syn is a nucleation-dependent process
with a lag phase, exponential growth phase, and development of a
steady state. In the lag phase, an aggregation nucleus, suggested
to be a dimer (22), is formed,which is preceded by the formation a
partially folded intermediate (23), and followed by oligomer
formation (24). In the exponential phase, oligomers grow into
protofibrils and finally into mature fibrils (25).
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We have found previously that the aggregation of R-syn is
accelerated in vitro by FK506 binding proteins (FKBPs) (26).
Early aggregate formation, followed with turbidity, was acceler-
ated by the addition of recombinant hFKBP12 in the micro-
molar range (26, 27). Fibril formation (measured by thioflavin T
fluorescence), however, was accelerated in the presence of
picomolar to nanomolar and micromolar concentrations of
hFKBP12. Addition of the inhibitor FK506 abolished the accel-
eration of fibril formation. An enzymatically inactive mutant of
hFKBP12 (D37L/F99Y) did not have any effect on fibril forma-
tion, confirming the importance of the enzymatic activity for the
effect of hFKBP12 on R-syn fibril formation. However, at
micromolar concentrations of theD37L/F99YhFKBP12mutant,
an acceleration of early aggregate formation was still observed
with turbidity, indicating that at these higher concentrations,
another type of interaction (e.g., merely binding) was involved.
FKBP12 belongs to the family of immunophilins, enzymes
that have a PPIase activity. These proteins catalyze the cis-trans
conformational change of a peptidyl-prolyl bond (X-Pro),
often the rate-limiting step in protein folding (28). The immuno-
suppressant FK506 inhibits the peptidyl-prolyl isomerase activ-
ity of FKBP12 (29-31).
FKBP12 is strongly expressed in the deep gray matter of
the human brain. A first indication that FKBP12 plays a role in
PD comes from the observation that its level of expression is
increased in a 6-OHDA rodent model of PD as well as in the
brain of PD patients (32, 33). Also, FKBP12 was found to often
colocalize with R-syn in LB and with tau in AD brain (34). We
have recently reported that overexpression and inhibition of
FKBP12 also affects R-syn aggregation in neuronal cells and in
mouse brain, demonstrating the physiological relevance of our
findings (35).
Parvulins and cyclophilins are non-FKBP members of the
family of immunophilins. Pin1, a human parvulin, has been
implicated in AD (36). Pin1 was also shown to colocalize with
R-syn in PD brain and to induce R-syn aggregation in cell
culture (37). These results link peptidyl-prolyl bond isomeriza-
tion to the pathogenesis of neurodegenerative diseases such as PD
and AD.
To further elucidate the role of proline residues in the
conformation and aggregation of R-syn, we constructed different
Pro-to-Ala mutants (PA), as well a mutant with all five proline
residuesmutated to alanine via site-directedmutagenesis (His-PA5
R-syn). The aggregation kinetics of these mutant R-syn’s were
studied with turbidity, thioflavin T fluorescence, and CD
measurements. We also analyzed the effect of hFKBP12 on
the aggregation of His-PA5 R-syn with turbidity and thioflavin
T fluorescence measurements. Finally, we also compared
the secondary structure of His-WT and His-PA5 R-syn with
circular dichroism.
EXPERIMENTAL PROCEDURES
Construction of R-syn Expression Plasmids and Purifi-
cation of Recombinant Protein. The proline mutants of R-syn
were constructed via site-directed mutagenesis using a two-step
polymerase chain reaction (PCR). The presence of the mutations
was confirmed by DNA sequencing. His-WT R-syn and the His-
PAmutant were purified as described previously (26, 27). Briefly,
BL21(DE3) PLysS Escherichia coli cells were transformed with
pRSET B R-syn (His-WT or His mutant). Cells were grown at
37 C in the presence of 100 μg/mL ampicillin and 30 μg/mL
chloramphenicol (Roth, Karlsruhe, Germany). Cells were in-
duced at an OD600 of 0.6 with 1 mM IPTG (Roth) and left
shaking for 3 h at 30 C. Cells were harvested and suspended in
50mL of sonication buffer [20mMHepes, 100 mMNaCl, 1 mM
PMSF, and 0.05 mM EDTA (pH 7.4)]. The lysate was frozen
overnight. After sonication (10 40 s, Branson sonifier 450), the
lysate was heated for 45 min at 65 C. The cell debris was pelleted
by centrifugation at 39100g for 30 min (Sorvall RC-24 refriger-
ated centrifuge, SLA-1500 rotor). The clear lysate was filtered
and subjected to Ni-Ted affinity chromatography (Macherey-
Nagel, D€uren, Germany). The fractions that contained R-syn
were pooled and applied to anion exchange chromatography
(Hitrap HP Q, GE Healthcare, Buckinghamshire, U.K.). The
column was washed with 20 mM Tris-HCl and 100 mM NaCl
(pH 8.0). A gradient was applied from 100 mM to 1MNaCl. All
fractions that contained R-syn were pooled and desalted on a
HiPrep 26/10 desalting column (GE healthcare). The sample was
eluted in 20 mM NH4HCO3 (pH 7.4) and lyophilized (Heto dry
winner model DW3, Heto Holten A/S, Allerod, Sweden). The
purity was checked via sodium dodecyl sulfate-polyacrylamide
gel electrophoresis (SDS-PAGE). WT R-syn was expressed
and purified as described previously (38). It was previously
shown that His-tagged R-syn forms the same fibrils as WT
R-syn (26, 27). Although His-WT R-syn fibrillates much slower
than R-syn, we also showed that hFKBP12 accelerates the
formation of fibrils of His-WT andWT R-syn to the same extent,
showing that the presence of the His tag does not substantially
affect the acceleration effect of hFKBP12 (Figure 1 of the
Supporting Information).
Purification of GST-FKBP12. The pGEX-2TK-FKBP12
expression plasmid was transformed in BL21(DE3) competent
cells. The cells were transferred to 5 mL LB cultures and
grown overnight in the presence of chloramphenicol (30 μg/mL)
and ampicillin (100 μg/mL) (Roth). Cells were transferred to
a 100 mL culture and grown overnight. The next morning, cells
were transferred to a 2 L culture and grown to an OD600 of 0.8.
The cells were induced with 1 mM IPTG (Roth) and left shaking
for 4 h at 28 C.Afterward, cells were harvested by centrifugation
and resolubilized in sonication buffer [20 mM Hepes, 1 mM
PMSF, and 1% Triton X-100 (pH 7.4)]. The pellet was frozen
overnight. After sonication, the lysate was filtered with a 0.45 μm
filter. The lysate was applied to glutathione Sepharose beads
(GE healthcare). The beads were washed with 20 mM Hepes,
1 mM PMSF, 100 mM NaCl, and 25 mM β-mercaptoethanol
(pH 7.4). The protein was eluted with 20 mM Hepes, 1 mM
PMSF, 100 mM NaCl, 25 mM β-mercaptoethanol, and 10 mM
reduced glutathione (pH 7.4). The purity was checked with
SDS-PAGE.
Peptidyl-Prolyl Cis-Trans Isomerase Activity. The
activity of GST-FKBP12 was measured via the method of
Kullertz et al. (39). Forty microliters of chymotrypsin [1 g/L
chymotrypsin in 35 mM Hepes (pH 7.8)] was added to a 4 μL
sample or 4 μL of 35 mM Hepes (pH 7.8) in the blank. The
reaction was monitored at 390 nm after the addition of 400 μL of
125 mg/mL succinimidyl-Phe-Pro-Phe-4-nitroanilide (Bachem).
Measurements were performed at room temperature. The data as
a function of time were fitted to the equation
y ¼ A0ð1- e- kobstÞþB0 ð1Þ
to obtain the first-order rate constant (k) of the cis-trans
isomerization reaction (A0 is the extrapolated absorbance at time
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zero, and B0 is the total increase in the magnitude of the ab-
sorbance signal). The specific enzymatic activity (kcat/KM) was
determined via the equation
kcat
KM
¼ kobs- k0½enzyme ð2Þ
where [enzyme] is the enzyme concentration used, k0 is the
observed rate constant of the uncatalyzed reaction, kobs is
the observed rate constant in the presence of FKBP12, and KM
is the Michaelis-Menten constant.
Turbidity Measurements. Lyophilized protein was dis-
solved in 20 mM Hepes, 150 mM NaCl, and 0.02% NaN3 (pH
7.4). Small aggregates were removed with the increase in the pH
of the sample to 11 with 0.6 NNaOH for 10 min, after which the
pH was lowered again to 7.4 by the addition of 0.6 N HCl (40).
Samples were centrifuged for 10 min at 14000 rpm (Eppendorf
tabletop centrifuge). Samples were incubated at 37 C in a 96-well
plate (Greiner Bio-one) while being shaken (∼270 rpm) in a
safire2 (Tecan, Mechelen, Belgium). The turbidity was measured
every 1000 s at 350 nm. All experiments were performed at least
three times, and representative graphs of these experiments are
shown.
Thioflavin T Measurements. Sample preparation was the
same as for the turbidity measurements with the exception
that 50 μM thioflavin T (Sigma Aldrich) was added prior to
the shaking (∼270 rpm) at 37 C. Every 1000 s, the sample was
measured by excitation at 446 nm and fluorescence emission was
detected at 482 nm.All experiments were performed at least three
times, and representative graphs of these experiments are shown.
Fitting of the Aggregation Curves. All the aggregation
curves were fitted to a sigmoid model with four parameters (41)
(using Sigmaplot 8.0).
y ¼ y0þ Δy
1þ e- kðt- t1=2Þ ð3Þ
where t1/2 is the half-time of aggregation, k is the rate constant of
aggregation determining the steepness of the curve,Δy is the total
increase in the magnitude of the signal, and y0 is the signal at time
zero (provided kt1/2 . 1) .
Circular Dichroism. Sample preparation was the same as for
the turbidity measurements. Far-UV CD measurements were
performed on a Jasco-800 spectrophotometer (Jasco, Ijsselstein,
The Netherlands) in a 0.1 cm path length cuvette (Hellma,
M€ullheim, Germany). The protein concentration was 0.2 mg/
mL [20 mMTris-HCl and 100 mMNaCl (pH 7.4)]. Spectra were
recorded at room temperature, from 195 to 260 nm with a step
size of 1 nm and a scanning speed of 20 nm/min. An average of
three scans were recorded. Spectra were corrected for the buffer
contribution. CD spectra were deconvoluted using the CDSSTR
algorithm (42) on Dichroweb (http://dichroweb.cryst.bbk.ac.uk/
html/home.shtml) (43, 44).
Transmission ElectronMicroscopy. Samples for transmis-
sion electronmicroscopy (TEM)were absorbed for 2min on 300-
mesh carbon-coated copper Formvar grids and stained for 1 min
with 1% uranyl acetate. Samples were examined with a JEOL
JEM 2100 LaB6 electron microscope operating at 200 keV.
RESULTS
Mutation of One orMore Proline Residues to Alanine in
the C-Terminal Part of R-syn Accelerates Its Aggregation
and Fibril Formation. We have shown previously with fluo-
rescence correlation spectroscopy, thioflavin T fluorescence, and
turbidity measurements that FK506 binding proteins accelerate
the aggregation of His-WT R-syn (26, 27). This effect was
dependent on the concentration of hFKBP12 and on its enzy-
matic activity, because it was significantly reduced in the presence
of the inhibitor FK506 or an enzymatically inactive mutant of
hFKBP12 (26, 27).
To elucidate the role of the different Pro residues in the
aggregation and fibril formation of R-syn, the kinetics of
aggregation of the constructed PA mutants of His-R-syn were
studied and compared with those of His-WT R-syn using
turbidity and ThT fluorescence measurements (Figure 1).
Turbidity measurements can be used to follow the formation
of any kind of large aggregates, and turbidity measurements of
His-WT R-syn show the formation of early, ThT negative
aggregates (26, 45, 46). An example of such aggregation curves
measured with turbidity is shown in Figure 2A.
The kinetics of fibril formation of His-WT R-syn and the
His-PAmutants were also studied with ThT fluorescence. ThT is
believed to bind specifically to the crossed β-structure typical for
amyloid fibrils, after which its fluorescence greatly increases (47).
Examples of such aggregation curves measured with ThT fluo-
rescence are shown in Figure 2B. The absorbance at 350 nm or
ThT fluorescence of His-WT R-syn and the His-PA mutants was
measured as a function of time in a 96-well plate under
continuous shaking (∼270 rpm). The measured aggregation
curves of every mutant were fitted with a sigmoidal curve with
four parameters (eq 3) to obtain the half-time of aggregation or
fibril formation, t1/2 (in hours). The means and standard devia-
tions of the half-time of aggregation and fibril formation for
every mutant were calculated for all measurements compared to
the half-time of aggregation (Table 1) or fibril formation (Table 2)
of His-WT R-syn (100%). Turbidity measurements show that the
aggregation of His-P108A R-syn, His-P117A R-syn, His-P120A
R-syn, His-P(108,117)A R-syn, His-P(108,117,120)A R-syn, and
FIGURE 1: Schematic representation of recombinant fusion proteins His-WT R-syn and the constructed PAmutants. The clinical mutations are
denotedwithblack arrows.The fivePro residues present in theC-terminus are denotedwith grayarrows.Themutated residues in everymutant are
colored white. The external tag is colored light gray, and the six histidine residues are colored dark gray.
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His-PA5 R-syn is faster than that of His-WT R-syn. The
kinetics of aggregation of His-P(120,128,138)A R-syn, how-
ever, are slower than the kinetics of aggregation of His-WT
R-syn (Figure 3).
From the ThT measurements, we can conclude that the fibril
formation of His-P108A R-syn, His-P117A R-syn, His-P120A
R-syn, His-P(108,117)A R-syn, His-P(120,128,138)A R-syn, and
His-PA5 R-syn is faster than that of His-WT R-syn. Fibril
formation of His-P(108,117,120)A R-syn, however, seems to be
only marginally faster than fibril formation of His-WT R-syn.
We also visualized the morphology of the aggregates of His-
WTR-syn and the constructedHis-PAR-synmutants with TEM.
Samples were taken at the end of the elongation phase. We could
show that His-WT R-syn andHis-PA5 R-syn (Figure 4) as well as
all the His-PA R-syn mutants (Figure 2 of the Supporting
Information) formed fibrils at the end of the elongation phase,
and that these fibrils resemble those found in LB (48).
The Effect of hFKBP12 on the Kinetics of Aggregation
of R-syn Is Lost When the Five Pro Residues in Its
C-Terminus AreMutated.We studied the effect of the enzyme
hFKBP12 on His-WT R-syn and His-PA5 R-syn. The activity of
the enzyme hFKBP12 was determined using a peptidyl-prolyl
bond activity assay. In this assay, the rate constant of the
cis-trans isomerization of the peptide bond preceding the Pro
residue is determined using the substrate succ-Phe-Pro-Phe-4-
nitroanilide. This rate constant was determined to be 2.3  106
M-1 s-1, which is consistent with the value of 1.2 106 M-1 s-1
determined by Tradler et al. (49).
We studied the effect of hFKBP12 on the aggregation kinetics
of His-WT R-syn and His-PA5 R-syn in a concentration range
(1 pM to 1 μM) with turbidity and ThT fluorescence measure-
ments. As controls, His-WT R-syn and His-PA5 R-syn without
the addition of hFKBP12 were used. The measured aggregation
curves (turbidity or ThT fluorescence) were fitted with a sigmoi-
dal model with four parameters to obtain the half-time of
aggregation for each curve. This half-time of aggregation was
normalized against the blank (His-WT or the studied mutant)
(100%) (n=3). Themean of threemeasurementswas calculated,
and the estimated standard error of the mean is shown in the
graphs. The accelerating effect of 1 μM hFKBP12 is present for
His-WT R-syn (Figure 5A). Mutation of all Pro residues to
alanine, however, abolishes the acceleration effect of hFKBP12
present in His-WT R-syn as measured with turbidity.
The kinetics of fibril formation of His-PA5 R-syn are clearly
independent of hFKBP12 concentration (Figure 5B).
The Proline Deficient Mutant Is More Structured Than
His-WT R-syn. To obtain additional insight into the signifi-
cance of our findings, we wanted to further study the conforma-
tion of the proline mutant compared to His-WT R-syn. There-
fore, we performed circular dichroismmeasurements at pH 7.4 to
reveal the secondary structure content of His-WT and His-PA5
FIGURE 2: Kinetics of aggregation (A) and fibril formation (B) of R-syn. R-syn (70 μM) was incubated at 37 C under continuous shaking
(∼270 rpm) in aTecanplate reader. (A)Turbiditymeasurement of aggregation as a functionof time forHis-WTR-syn (O) andHis-PA5R-syn (4).
(B) ThT fluorescence measurement of the time-dependent fibril formation of His-WT R-syn (O) and His-PA5 R-syn (4). The horizontal bars
represent estimated standard deviations.
Table 1: Half-Times of Aggregation of the PA Mutants and His-WTa
protein turbidity t1/2 (%)
His-WT R-syn 100
His-P108A R-syn 77( 7 (n=4)
His-P117A R-syn 66( 6 (n=3)
His-P120A R-syn 71( 6 (n=3)
His-P(108,117)A R-syn 60( 10 (n=7)
His-P(108,117,120)A R-syn 77( 9 (n=5)
His-P(120,128,138)A R-syn 116( 10 (n=3)
His-PA5 R-syn 74 ( 6 (n=7)
aThe half-times of aggregation of the PA mutants are expressed as a
percentage of the half-time of aggregation of the control His-WT. The
means and estimated standard errors of the mean and the number of
measurements (n) are given.
Table 2: Half-Times of Fibril Formation of the His-PA Mutants and
His-WTa
protein ThT t1/2 (%)
His-WT R-syn 100
His-P108A R-syn 52( 11 (n=8)
His-P117A R-syn 44( 12 (n=5)
His-P120A R-syn 56( 11 (n=5)
His-P(108,117)A R-syn 54( 8 (n=6)
His-P(108,117,120)A R-syn 86( 15 (n=9)
His-P(120,128,138)A R-syn 41( 5 (n=5)
His-PA5 R-syn 51 ( 7 (n=10)
aThe half-times of fibril formation of the His-PA mutants are expressed
as a percentage of the half-time of aggregation of the control His-WT. The
means and estimated standard errors of the mean and the number of
measurements (n) are given.
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R-syn. The published CD spectra of R-syn show a pronounced
minimum around 198 nm (approximately -14000 deg cm2
dmol-1) and a shoulder around 220 nm (approximately -2000
deg cm2 dmol-1) (16, 50, 51) characteristic of a high random coil
content (64%) and some β-sheet (19%) (51). Our His-WT R-syn
shows aminimum that ismuch less pronounced (at 205 nmwith a
mean residue ellipticity of approximately-2600 deg cm2 dmol-1)
and the same shoulder at 220 nm (Figure 6). This is partially
due to the contribution of the longHis tail (37 extra amino acids)
and its potential effect on the structure of R-syn. Secondary
structure analysis [using the CDSSTR algorithm (42)] shows
that His-WT R-syn has a higher R-helix content (34%) and
lower random coil content (51.7%, including turns) thanR-syn.
The mutant protein His-PA5 R-syn has a slightly deeper
minimum at 205 nm (-3250 deg cm2 dmol-1) and a higher
shoulder level at 220 nm (-1500 deg cm2 dmol-1). The proline
mutant His-PA5 R-syn is clearly more structured (42% R-helix)
but has a lower β-content (12.6%) than His-WT R-syn accord-
ing to the numerical analysis.
Aggregation Kinetics Studied with CD Measurements.
The changes in the secondary structure of 70 μM His-WT and
mutant His-PA5 R-syn as a function of aggregation time were
measured with CD. His-WT R-syn and the mutant His-PA5
R-syn were incubated at 37 C [20 mM Tris-HCl and 150 mM
NaCl (pH 7.4)] under continuous stirring (∼500 rpm). The
spectra were recorded at room temperature.
During the aggregation process, the spectra of the Pro deficient
mutant and His-WT R-syn are changing with an increase in the
ellipticity around 200 nm and a decrease in the shoulder at
220 nm, indicating an increasingβ-sheet structure content (Figure 7).
His-PA5 R-syn already shows an increase of β-sheet after
29 h in the aggregation process, while His-WT R-syn does not
show any indication for that even after aggregation for 45 h
(Figure 7B). Thus, the kinetics ofβ-sheet formation of themutant
are accelerated compared to those of His-WT R-syn. This is in
accordance with the results obtained from the turbidity and ThT
fluorescence measurements. In conclusion, CD measurements
also demonstrate that the kinetics of β-sheet formation of the
proline deficient mutant R-syn are significantly accelerated
compared to those of the His-WT protein.
DISCUSSION
It was reported by our group that hFKBP12 and slyD
accelerate the aggregation of R-syn in vitro (26), and this
accelerating effect proved to be concentration-dependent (27).
SlyD and hFKBP12 are enzymes that have a PPIase activity, thus
catalyzing the slow cis-trans conformational change of an
X-Pro peptide bond. The physiological relevance of these
findings was demonstrated by the fact that overexpression and
inhibition of hFKBP12 also affect R-syn aggregation in neuronal
cells and in mouse brain (35).
Role of Pro Residues in the Aggregation Kinetics of
R-syn. To further elucidate the role of the Pro residues, several
mutants, in which one ormore Pro residues were mutated to Ala,
were constructed and purified (Figure 1). This is a generally
accepted procedure for determining if a Pro residue in a protein is
essential for folding (52, 53). We have used three methods to
study the kinetics of aggregation, i.e., turbidity, ThT fluores-
cence, and CDmeasurements. We show that mutation of one or
more Pro residues modifies the aggregation kinetics of R-syn,
because His-P108A, His-P117A, His-P120A, His-P(108,117)A,
His-P(108,117,120)A, and His-PA5 R-syn aggregate faster than
His-WT R-syn. Therefore, it appears that mutation of the
individual prolines (P108, P117, and/or P120) to Ala increases
the rate of aggregation of R-syn.
Also, the kinetics of fibril formation, as measured with
ThT fluorescence, are accelerated in the mutants His-P108A,
FIGURE 3: (A) Half-times of aggregation obtained from turbidity measurements of His-WT R-syn and all the constructed His-PAmutants, after
the data had been fit to eq 3 for a sigmoidal model. The half-time of aggregation of the mutants is expressed as a percentage of the half-time of
aggregation of the control His-WT R-syn. (B) Half-times of fibril formation of His-WT R-syn and the His-PA mutants as obtained from ThT
fluorescencemeasurements after the data had been fit to eq 3. The half-time of aggregation of themutants is expressed as a percentage of the half-
time of aggregation of the control His-WT R-syn.
FIGURE 4: TEM images of (A)His-WTR-syn and (B)His-PA5R-syn
incubated at 37 C under continuous shaking. The scale bar repre-
sents 200 nm. Similar fibrils are observed in all samples.
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His-P117A, His-P120A, His-P(108,117)A, His-P(120,128,138)A,
and His-PA5 R-syn. Multiple replacements of Pro do not seem
to lead to additional acceleration, and surprisingly enough,
triple mutant His-P(108,117,120)A R-syn forms fibrils as fast as
His-WT R-syn. This suggests that the effect of the Pro mutations
is not additive and that the mutation of more than two Pro
residues can cancel the effect of the others.
The extent of acceleration is larger for fibril formation than for
aggregate formation. This suggests that the conformation of the
Pro residues plays a more important role in the process of fibril
formation than in early aggregate formation.
It should be remarked that for His-WT R-syn the turbidity
increase precedes the ThT increase, indicating the formation
of non-β intermediates, either on or off pathway. For His-PA5
R-syn, fibril formation is accelerated more than aggregation,
making the two curves almost coincide (see Figure 2). This seems
to suggest that in the latter case intermediates are formed that
convert more rapidly into fibrils. The situation is different for
mutant P(120,128,138)A R-syn, in which the turbidity increase is
retarded relative to that of WT, while fibril formation is only
slightly accelerated. Not all combinations of three Pro mutations
lead to this remarkable effect. It is clear that the single and double
PAmutations generally create a conformation that is more prone
to aggregation and allow a faster intramolecular reorganization
leading to the β-sheet structures necessary for fibril formation,
analogous to the “curing” process in polymers.
Loss of the Accelerating Effect of hFKBP12. We also
show that the accelerating effect of hFKBP12 is lost in His-PA5
R-syn, supporting the interpretation of the catalytic effect of the
enzyme. The accelerating effect at 1 μMhFKBP12was suggested
to be a nonenzymatic effect, which would imply that the enzyme
would bind at the Pro motif, and mutation of these Pro residues
to Ala might abrogate the binding of hFKBP12 to R-syn.
An increase in the rate of fibril formation can be seen at both
low (picomolar to nanomolar) and high (micromolar) concen-
trations of hFKBP12. When hFKBP12 is added at higher
concentrations, there can be still a binding effect. Addition of
hFKBP12 to theHis-PA5R-synmutant, however, decelerated the
aggregation. We cannot easily explain this decelerating effect of
hFKBP12 on the fibril formation of His-PA5 R-syn with the
experiments that have been performed. This effect, however,
could arise from the binding of hFKBP12 on a distinct binding
site other than the Pro rich sequence, or the stabilization of a
conformation that is less active in aggregation.
Role of the Pro Residues in the Conformation of R-syn.
To study the role of the Pro residues with respect to the
conformation of R-syn, far-UV CD spectra of His-WT R-syn
and His-PA5 R-syn were recorded under physiological condi-
tions, before aggregation. The numerical analysis of the mea-
sured CD spectra suggests that His-PA5 R-syn is more folded
than His-WT R-syn. On the basis of the obtained results, we can
propose the following hypothetical mechanism. It has been
shown before that the C-terminus plays a regulating role in the
fibril formation of R-syn (16, 54), and this domain is not
incorporated into the core of the fibril (18, 55-57). When the
charge or hydrophobicity of the C-terminus is changed or the
C-terminus is deleted, the rate of aggregation is enhanced in vitro
and in cells (16, 50, 54, 58, 59). The C-terminal domain of R-syn
protects the NAC domain with its high charge and low hydro-
phobicity (16). From our results, we can add that the five proline
residues also help to prevent the formation of an aggregation-
prone conformation. Thus, changing the Pro residues into Ala
residues and switching to the all-trans conformation probably
extend theC-terminus and reduce the level of shielding of theNAC
domain and thus accelerate aggregation and fibril formation.
R-syn contains five Pro residues, located in the C-terminal
domain of the protein. In principle, the X-Pro peptide bond
can be found in both cis and trans conformations in a peptide
backbone, which implies that the C-terminus can adopt 25
FIGURE 5: Effect of hFKBP12 on the aggregation kinetics of His-WT R-syn (gray) and His-PA5 R-syn (black). Aggregation kinetics were
measured with (A) turbidity and (B) ThT fluorescence. Proteins were incubated at 37 C under continuous shaking (∼270 rpm).
FIGURE 6: Far-UVCD spectrumofHis-WTR-syn (---) andHis-PA5
R-syn (;). Spectrawere recordedat room temperature.Compared to
the CD spectrumofWTR-syn, theminimum around 200 nm ismuch
less pronounced and shifted to ∼205 nm, indicating the follow-
ing order ofR-helix content: His-PA5 R-syn>His-WTR-syn>WT
R-syn.
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possible conformations. Because R-syn is an intrinsically un-
structured protein, this is theoretically possible. However, be-
cause our CDmeasurements on the PA5 R-syn mutant show that
this protein has more structure than WT R-syn, it seems likely
that at least some Pro residues exist only or mainly in their cis
conformation and in this way favor the inhibitory conformation
of the C-terminus (20).
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